TABLE 3.
Performance of Morphologic Assessment and p57 Immunostaining for Predicting a Genotyping-Confirmed Diagnosis of PHM
| Diagnosis of PHM (PHM vs. CHM+NM) | Sensitivity (%) | Specificity (%) | Positive Predictive Value (%) | Negative Predictive Value (%) |
|---|---|---|---|---|
| Pathologist 1 | ||||
| Round 1 | 59 | 58 | 42 | 74 |
| Round 2 | 70 | 74 | 58 | 83 |
| Round 3 (p57) | 85 | 70 | 59 | 90 |
| Pathologist 2 | ||||
| Round 1 | 93 | 68 | 60 | 95 |
| Round 2 | 74 | 79 | 65 | 86 |
| Round 3 (p57) | 78 | 77 | 64 | 87 |
| Pathologist 3 | ||||
| Round 1 | 56 | 81 | 60 | 78 |
| Round 2 | 59 | 92 | 80 | 82 |
| Round 3 (p57) | 56 | 94 | 83 | 81 |
| Consensus diagnosis | ||||
| Round 1 | 78 | 74 | 60 | 87 |
| Round 2 | 70 | 85 | 70 | 85 |
| Round 3 (p57) | 78 | 83 | 70 | 88 |
CHM indicates complete hydatidiform mole (either classic or early type); NM, non-molar specimen; PHM, partial hydatidiform mole.